Romosozumab versus teriparatide – Nature.com

Romosozumab versus teriparatideNature.comThe effect of two bone-forming agents — the anti-sclerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been …

Source:: Osteoporosis Feed

      

Last modified: August 9, 2017